Moreover, the expression of MAP1LC3B, ATG5, ATG10, RB1CC1, and AMBRA1 genes was assessed in seven AML patients in the relapse phase and compared with that of 32 newly diagnosed AML patients. The gene discussed is RB1CC1; the disease is acute myeloid leukemia.